Amryt Pharma (NASDAQ:AMYT) Hits New 12-Month High at $14.59

Amryt Pharma plc (NASDAQ:AMYTGet Rating)’s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $14.59 and last traded at $14.54, with a volume of 57214 shares traded. The stock had previously closed at $7.00.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on AMYT. Cantor Fitzgerald cut shares of Amryt Pharma from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $25.00 to $14.75 in a research report on Tuesday. SVB Leerink cut shares of Amryt Pharma from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $19.00 to $14.50 in a research report on Monday. Maxim Group cut shares of Amryt Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Canaccord Genuity Group restated a “hold” rating and issued a $17.00 price objective (down previously from $19.00) on shares of Amryt Pharma in a research report on Tuesday. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Amryt Pharma presently has an average rating of “Hold” and an average target price of $16.88.

Amryt Pharma Stock Up 0.5 %

The company has a market cap of $932.58 million, a P/E ratio of -243.00 and a beta of 0.27. The company has a current ratio of 1.57, a quick ratio of 0.94 and a debt-to-equity ratio of 0.64. The firm’s 50 day moving average price is $7.45 and its 200-day moving average price is $7.36.

Amryt Pharma (NASDAQ:AMYTGet Rating) last issued its earnings results on Thursday, November 3rd. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The business had revenue of $61.13 million during the quarter, compared to the consensus estimate of $66.00 million. Amryt Pharma had a negative net margin of 8.19% and a positive return on equity of 1.70%. As a group, equities research analysts expect that Amryt Pharma plc will post -0.09 EPS for the current year.

Hedge Funds Weigh In On Amryt Pharma

A number of institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its position in Amryt Pharma by 66,352.9% during the third quarter. Royal Bank of Canada now owns 11,297 shares of the company’s stock worth $78,000 after purchasing an additional 11,280 shares during the period. Virtu Financial LLC bought a new position in Amryt Pharma during the second quarter worth $114,000. State Street Corp bought a new position in Amryt Pharma during the third quarter worth $134,000. Hsbc Holdings PLC bought a new position in Amryt Pharma during the first quarter worth $202,000. Finally, Renaissance Technologies LLC boosted its position in Amryt Pharma by 44.1% during the first quarter. Renaissance Technologies LLC now owns 25,800 shares of the company’s stock worth $213,000 after purchasing an additional 7,900 shares during the period. 71.31% of the stock is currently owned by institutional investors and hedge funds.

About Amryt Pharma

(Get Rating)

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia.

Read More

Receive News & Ratings for Amryt Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma and related companies with MarketBeat.com's FREE daily email newsletter.